Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$16.48 - $27.23 $3.41 Million - $5.63 Million
-206,927 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$20.0 - $25.48 $138,540 - $176,499
6,927 Added 3.46%
206,927 $4.36 Million
Q1 2021

May 17, 2021

BUY
$16.14 - $29.11 $3.23 Million - $5.82 Million
200,000 New
200,000 $4.18 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $1.92B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.